3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Expanded_access
1
Sponsor
Conditions
Breast Neoplasms
41
Neoplasm Metastasis
11
Hereditary Sensory and Autonomic Neuropathies
6
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Ovarian Neoplasms
5
Neoplasms
5
Triple Negative Breast Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Head and Neck Neoplasms
3
Pancreatic Neoplasms
2
Melanoma
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Hyperglycemia
2
Head and Neck Squamous Cell Cancer
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Advanced Breast Cancer
2
Vascular Malformations
1
Uveal Melanoma
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Interventions
Alpelisib
2
mirdametinib
1
Sirolimus
1
Sildenafil Citrate
1
Picibanil
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Lymphangioma
×
Alpelisib
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled